N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 4 ClinicalTrials.gov

Demedetomidine and Remifentanil in Electroconvulsive Therapy (ECT)

Sponsor: Inonu University • ClinicalTrials.gov ID: NCT07824817

Registry updated: 2026-09-29
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

Electroconvulsive therapy (ECT) is a treatment modality that induces therapeutic seizures through electrical stimulation for the management of certain psychiatric disorders. Nearly all ECT procedures are performed under general anesthesia. However, ECT is commonly associated with acute hyperdynamic responses immediately following electrical stimulation, including transient hypertension and tachycardia. These acute hemodynamic changes may pose significant risks, particularly in patients with ischemic heart disease, hypertension, or cerebrovascular disease. Therefore, the hemodynamic response, seizure quality, and recovery profile are critical factors influencing the choice of anesthetic and adjuvant agents. The primary goal of anesthesia for ECT is to maintain hemodynamic stability without compromising seizure duration or quality while ensuring rapid and safe recovery

Interventions

  • Saline (0.9% NaCl) (Drug)
    Saline will infused over 10 minutes (total volume: 30 mL)
  • Dexmedetomidine (Drug)
    Dexmedetomidine at a dose of 0.5 μg/kg will infused over 10 minutes (total volume: 30 mL)
  • Remifentanil (Drug)
    Remifentanil at a dose of 1 μg/kg will infused over 10 minutes (total 30 ml)

Eligibility criteria

Inclusion Criteria: * Upremedicated ASA I-II (American Society of Anesthesiologists's physical status) patients, * Patients scheduled for six ECT sessions for a variety of psychiatric conditions Exclusion Criteria: * refusal to participate, * age below 18 or above 60 years * pregnancy * asthma * current use of β-adrenergic blockers * myocardial infarction within the previous six months * atrial fibrillation or atrial flutter, * heart block * a known personal or family history of hypersensitivity to any of the study drugs

Conditions

Hemodynamic Response

Locations

  • Inonu Universitesi Turgut Ozal Tıp Merkezi — Malatya, Battalgazi, Turkey (Türkiye)
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record